Linkage Infrastructure, Equipment And Facilities - Grant ID: LE240100134
Funder
Australian Research Council
Funding Amount
$796,206.00
Summary
Super-resolution platform to accelerate biological and molecular research. This application aims to establish a new molecular analysis platform integrating a microfluid capillary electrophoresis interface directly to a mass spectrometer with advanced data scanning technology. This enables label-free detection, quantitation and characterisation of intact proteins, lipids and metabolites with unprecedented sensitivity, resolution and throughput. It will enhance ARC projects spanning natural produc ....Super-resolution platform to accelerate biological and molecular research. This application aims to establish a new molecular analysis platform integrating a microfluid capillary electrophoresis interface directly to a mass spectrometer with advanced data scanning technology. This enables label-free detection, quantitation and characterisation of intact proteins, lipids and metabolites with unprecedented sensitivity, resolution and throughput. It will enhance ARC projects spanning natural product discovery, biotechnology, agriculture, and animal, plant and marine biology, as well as single-cell proteomics, lipidomics and metabolomics. It will ensure Australia remains at the forefront of molecular and biological research and create new training and collaborative opportunities both nationally and internationally.Read moreRead less
Discovery and development of novel insulin sensitising compounds for the treatment of Type 2 diabetes. Diabetes is one of the major health problems facing Australia today, and current treatments are proving inadequate to combat this disease. We previously discovered a new drug with potential for development for the treatment of diabetes. In this project, we will identify how this drug works to combat diabetes in cell and animal models, and use novel chemistry approaches to modify the drug to imp ....Discovery and development of novel insulin sensitising compounds for the treatment of Type 2 diabetes. Diabetes is one of the major health problems facing Australia today, and current treatments are proving inadequate to combat this disease. We previously discovered a new drug with potential for development for the treatment of diabetes. In this project, we will identify how this drug works to combat diabetes in cell and animal models, and use novel chemistry approaches to modify the drug to improve its properties and reduce potential side-effects. The outcomes of this project will be understanding of a new biological process that contributes to the development of diabetes, and the discovery and characterisation of new chemical compounds that could be developed as drugs to treat diabetes.Read moreRead less
Bioactive Peptides as Pharmacological Tools and Novel Drug Leads. Bioactive peptides are produced by all organisms and play numerous critical physiological roles, including in cellular communication, host defence and capture of prey. Peptides have huge potential as tools for studying roles of signalling pathways and as novel drugs due to their high affinity and selectivity for various therapeutically relevant targets. However their use has been limited by poor in vivo stability. This project is ....Bioactive Peptides as Pharmacological Tools and Novel Drug Leads. Bioactive peptides are produced by all organisms and play numerous critical physiological roles, including in cellular communication, host defence and capture of prey. Peptides have huge potential as tools for studying roles of signalling pathways and as novel drugs due to their high affinity and selectivity for various therapeutically relevant targets. However their use has been limited by poor in vivo stability. This project is focused on studying structural features of a range of peptides and their contributions to both activity and to resistance against degradation, with the aim to develop stabilised bioactive peptide sequences for in vivo applications, allowing the full potential of peptides as drugs to be realised.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE160100047
Funder
Australian Research Council
Funding Amount
$380,000.00
Summary
Distributed facility for fragment based drug discovery. Distributed facility for fragment based drug discovery:
The facility aims to provide researchers with the ability to generate small molecules that modulate therapeutically and biologically important protein targets. Fragment-based drug design (FBDD) provides a rational approach to generate such biologically active compounds. The facility is designed to allow researchers throughout Australia to access the necessary infrastructure to underta ....Distributed facility for fragment based drug discovery. Distributed facility for fragment based drug discovery:
The facility aims to provide researchers with the ability to generate small molecules that modulate therapeutically and biologically important protein targets. Fragment-based drug design (FBDD) provides a rational approach to generate such biologically active compounds. The facility is designed to allow researchers throughout Australia to access the necessary infrastructure to undertake FBDD projects against a range of biologically important targets. The facility aims to enable access to high-throughput nuclear magnetic resonance spectroscopy and surface plasmon resonance, and to generate the capacity for automation in chemical synthesis and sample preparation to expedite the development of novel bioactive molecules. The development of better approaches to hit development may benefit many researchers in Australia employing FBDD.Read moreRead less
New approaches to inhibition of activity of HIV integrase. This project aims to assist in the development of novel anti-HIV drugs that will benefit the 17000 Australians and more than 33 million people worldwide who are currently suffering with this terrible disease. The project will utilise state-of-the-art approaches in structure-based drug design to identify and synthesise compounds as leads for the development of anti-HIV drugs. Furthermore, the project will provide invaluable training for t ....New approaches to inhibition of activity of HIV integrase. This project aims to assist in the development of novel anti-HIV drugs that will benefit the 17000 Australians and more than 33 million people worldwide who are currently suffering with this terrible disease. The project will utilise state-of-the-art approaches in structure-based drug design to identify and synthesise compounds as leads for the development of anti-HIV drugs. Furthermore, the project will provide invaluable training for the researchers involved and enhance the relationship between the academic and commercial collaborators.Read moreRead less
Inhibition of membrane-bound carbonic anhydrases with small molecules as a novel approach to target a safe and effective treatment for solid tumours. Over 85 per cent of human cancers are solid tumours and the prognosis for patients with advanced solid tumours is extremely poor owing to resistance to conventional chemo- and radio- therapies. Our research will underpin the development of new, safe and effective drug treatment options for cancer patients with solid tumours.
Lymphotropic prodrugs: a novel mechanism for targeted drug delivery. This project aims to design chemically modified drugs that target drug delivery specifically to white blood cells. This approach promises to maximise drug action and simultaneously reduce toxicity for diseases where lymphocytes are the major drug target. These include autoimmune disease, leukaemia, lymphoma, HIV, transplant rejection and diabetes.
Structure-based design of inhibitors of HIV-1 integrase. This project will produce compounds that block human immunodeficiency virus (HIV) replication. These compounds will benefit the 17000 Australians and more than 34 million people worldwide who are currently suffering with this terrible disease.
Mid-Career Industry Fellowships - Grant ID: IM230100534
Funder
Australian Research Council
Funding Amount
$874,096.00
Summary
NOVEL MASS-SCALE BIOSYNTHESIS: TAILORING CHEMICAL LOGIC & BIOSYNTHESIS. No new antibiotics against Gram-negative ‘superbugs’ are expected to be available in the near future. We have exhausted the chemical space from the natural product pool and lack a fundamental understanding of antibiotics in nature, this is a major hurdle for antibiotic design targeting bacterial resistance. This proposal aims to engineer unique chemo-enzymatic platforms for the synthesis of new lipopeptide scaffolds which wi ....NOVEL MASS-SCALE BIOSYNTHESIS: TAILORING CHEMICAL LOGIC & BIOSYNTHESIS. No new antibiotics against Gram-negative ‘superbugs’ are expected to be available in the near future. We have exhausted the chemical space from the natural product pool and lack a fundamental understanding of antibiotics in nature, this is a major hurdle for antibiotic design targeting bacterial resistance. This proposal aims to engineer unique chemo-enzymatic platforms for the synthesis of new lipopeptide scaffolds which will significantly expand the chemical space available for novel antibiotic discovery. The development of these unique platforms will greatly expand our inventory of natural product antibiotics and will represent a major technological break-through for Australia's biotechnology and pharmaceutical manufacturing sectors.Read moreRead less